Suggested remit: To appraise the clinical and cost effectiveness of foslevodopa-foscarbidopa subcutaneous infusion within its marketing authorisation for treating Parkinson’s disease with motor symptoms [ID3876]
 
Status In progress
Technology type Medicine
Decision Selected
Process STA 2022
ID number 3876

Provisional Schedule

Committee meeting: 1 14 February 2023
Expected publication 03 May 2023

Project Team

Project lead Louise Jafferally

Email enquiries

Stakeholders

Companies sponsors AbbVie (foslevodopa-foscarbidopa)
Others Department of Health and Social Care
  NHS England
  NHS Herts Valleys CCG
  NHS North Norfolk CCG
  Welsh Government
Patient carer groups Brain and Spine Foundation
  Brain Charity
  Dementia Carers Count
  Dementia UK
  Innovations in Dementia
  Neurological Alliance
  Parkinson’s UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Sue Ryder
Professional groups Association of British Neurologists
  Association of Directors of Adult Social Services
  British Association for Psychopharmacology
  British Association of Neuroscience Nurses
  British Geriatrics Society
  British Neuropathological Society
  British Neuropsychiatry Association
  Institute of Neurology
  Neuromodulation Society of UK and Ireland
  Parkinson’s Disease Nurse Specialist Association
  Primary Care and Community Neurology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies AbbVie (levodopa-carbidopa intestinal gel)
  Accord Healthcare (pramipexole, ropinirole, rasagiline)
  Aspire Pharma (pramipexole)
  Aurobindo Pharma (pramipexole, ropinirole, rasagiline)
  Bial Pharma UK (opicapone)
  Boehringer Ingelheim (pramipexole)
  Britannia Pharmaceuticals (apomorphine)
  Bown and Burk UK (rasagiline)
  Dr Reddy's Laboratories UK (rasagiline)
  Ever Pharma UK (apomorphine)
  Fontus Health (amantadine)
  GlaxoSmithKline UK (ropinirole)
  Glenmark Pharmaceuticals (pramipexole, rasagiline)
  Lupin Healthcare UK (ropinirole)
  Martindale Pharma (pramipexole, ropinirole)
  Meda Pharmaceuticals (tolcapone)
  Mylan (pramipexole, ropinirole, bromocriptine)
  Orion Pharma (selegiline, entacapone)
  Pfizer (cabergoline)
  Profile Pharma (safinamide)
  Rivopharm UK (rasagiline)
  Teva Pharmaceuticals (rasagiline)
  UCB Pharma (rotigotine)
  Zentiva (pramipexole, rasagiline)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Health Specialised Services Committee
Relevant research groups Brain Research UK
  British Neurological Research Trust
  Cochrane UK
  Cure Parkinson’s
  Genomics England
  Institute for Ageing and Health
  MRC Clinical Trials Unit
  National Hospital for Neurology and Neurosurgery
  National Institute for Health Research
  Research Institute for the Care of Older People
  UK Parkinson’s Disease Consortium

Timeline

Key events during the development of the guidance:

Date Update
21 April 2022 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and submissions from all stakeholders are now due on Tuesday 16 August 2022.
07 April 2022 Invitation to participate
07 April 2022 In progress. ITP issued
21 October 2021 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early April 2022 when we will write to consultees and commentators about how they can get involved.
23 July 2021 Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early January 2022 when we will write to you about how you can get involved.
07 May 2021 Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late October 2021.
21 April 2021 (10:00) Scoping workshop
01 March 2021 - 29 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual